Research News

Adding chemotherapy to hormonal therapy prolongs survival in metastatic prostate cancer, study finds

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4253 (Published 06 August 2015) Cite this as: BMJ 2015;351:h4253
  1. Susan Mayor
  1. 1London

Adding chemotherapy to androgen deprivation therapy significantly prolongs survival more than hormonal therapy alone in men with hormone sensitive metastatic prostate cancer, shows a randomised study reported in the New England Journal of Medicine.1

Androgen deprivation therapy has been the backbone of the treatment for metastatic prostate cancer since the 1940s, but most patients become resistant to this treatment over time, and the median survival is currently around three years. The potential benefit of adding chemotherapy has been unclear, but …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe